Determining the potency and molecular mechanism of action of insurmountable antagonists

被引:148
作者
Kenakin, Terry
Jenkinson, Stephen
Watson, Christian
机构
[1] GlaxoSmithKline Res & Dev Ltd, Dept Assay Dev, Res Triangle Pk, NC 27709 USA
[2] GlaxoSmithKline Res & Dev Ltd, Dept Biochem & Analyt Pharmacol, Res Triangle Pk, NC 27709 USA
关键词
D O I
10.1124/jpet.106.107375
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Insurmountable antagonism (maximal response to the agonist depressed) can result from a temporal inequilibrium involving a slow offset orthosteric antagonist or be the result of an allosteric modulation of the receptor. The former mechanism is operative when the antagonist, agonist, and receptors cannot come to proper equilibrium during the time allotted for collection of agonist response (hemi-equilibrium conditions). Allosteric effects (changes in the conformation of the receptor through binding of the allosteric modulator to a separate site) can preclude the agonist-induced production of response, leading to depression of maximal responses. In these cases, the effects on receptor affinity can be observed as well. The first premise of this article is that system-independent estimates of insurmountable antagonist potency can be made with no prior knowledge of molecular mechanism through the use of pA(2) (-log molar concentration of antagonist producing a 2-fold shift of the concentration response curve) measurements The relationship between the pA(2) and antagonist pK(B) (-log equilibrium dissociation constant of the antagonist-receptor complex) is described; the former is an extremely close approximation of the latter in most cases. The second premise is that specially designed experiments are required to differentiate orthosteric versus allosteric mechanisms; simply fitting of data to orthosteric or allosteric theoretical models can lead to ambiguous results. A strategy to determine whether the observed antagonism is orthosteric (agonist and antagonist competing for the same binding site on the receptor) or allosteric in nature is described that involves the detection of the hallmarks of allosteric response, namely saturation and probe dependence of effect.
引用
收藏
页码:710 / 723
页数:14
相关论文
共 32 条
[11]   HIV-1 Entry Cofactor: Functional cDNA Cloing of a Seven-Transmembrane, G protein-Coupled Receptor [J].
Feng, Yu ;
Broder, Christopher C. ;
Kennedy, Paul E. ;
Berger, Edward A. .
JOURNAL OF IMMUNOLOGY, 2011, 186 (11) :872-877
[12]  
GADDUM J H, 1955, Q J Exp Physiol Cogn Med Sci, V40, P49
[13]  
Gaddum J.H., 1937, J PHYSIOL-LONDON, V89, p7P
[14]  
GADDUM JH, 1957, PHARMACOL REV, V9, P211
[15]   Modeling the functional effects of allosteric modulators at pharmacological receptors: An extension of the two-state model of receptor activation [J].
Hall, DA .
MOLECULAR PHARMACOLOGY, 2000, 58 (06) :1412-1423
[16]   Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors [J].
Jakubik, J ;
Bacakova, L ;
ElFakahany, EE ;
Tucek, S .
MOLECULAR PHARMACOLOGY, 1997, 52 (01) :172-179
[17]   New concepts in drug discovery: Collateral efficacy and permissive antagonism [J].
Kenakin, T .
NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (11) :919-927
[18]   Allosteric modulators: The new generation of receptor antagonist [J].
Kenakin, T .
MOLECULAR INTERVENTIONS, 2004, 4 (04) :222-229
[19]   G-protein coupled receptors as allosteric machines [J].
Kenakin, T .
RECEPTORS & CHANNELS, 2004, 10 (02) :51-60
[20]   Tachykinin-induced contraction of the guinea-pig isolated oesophageal mucosa is mediated by NK2 receptors [J].
Kerr, KP ;
Thai, B ;
Coupar, IM .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 131 (07) :1461-1467